TABLE 2.
ML-145 displays greater potency as an antagonist at human GPR35 than CID-2745687
Human GPR35-β-arrestin-2 interaction assays were conducted by using EC80 amounts of the indicated agonists and varying concentrations of either ML-145 or CID-2745687. In all cases a maximally effective concentration of either antagonist ligand was able to fully reverse the effects of the agonist ligand. Data are means ± S.E.M. from nine independent experiments.
| Agonist | Antagonist |
|
|---|---|---|
| ML-145 | CID-2745687 | |
| Zaprinast | 7.57 ± 0.07 | 6.70 ± 0.09 |
| Cromolyn disodium | 7.65 ± 0.07 | 6.27 ± 0.08 |
| Pamoate | 8.08 ± 0.12 | 7.16 ± 0.12 |